Overview

SMP-3124LP in Adults With Advanced Solid Tumors

Status:
RECRUITING

Trial end date:
2029-05-01

Target enrollment:

Participant gender:

Summary

An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors

Phase:

PHASE1

Details

Lead Sponsor:

Sumitomo Pharma America, Inc.